There’s a moment most MedTech CEOs know well.

The sales pipeline is inconsistent. The marketing calendar fills with activity that doesn’t visibly connect to revenue. The board asks about go-to-market, and the answer keeps getting longer and less clear.

The CEO is fielding tactical questions that somebody else should own.

At some point, the obvious answer surfaces: We need a CMO.

And then nobody hires one.

Not this quarter, anyway. Maybe next quarter, when a deal closes. When the raise finishes. When the product has a little more traction.

There’s always a reason to wait. And the waiting always feels responsible.

What often doesn’t get calculated is what the waiting actually costs.

The Real Cost of a Full-Time CMO

A senior MedTech CMO is a significant investment.

Beyond salary, there are benefits, employer taxes, equity, recruitment costs and the time it takes for a new executive to understand the business.

But the biggest cost is often less obvious.

It’s the gap between deciding you need senior commercial leadership and having that leadership actually working inside the business.

A new CMO needs time to understand your clinical evidence, buyers, sales process, market position and competitive landscape.

They need to understand what has already been tried. They need to understand what the sales team hears from customers. They need to understand what investors expect.

Only then can they start making high-confidence strategic decisions.

That takes time.

For a MedTech company moving toward commercial scale, that time matters.

You’re not simply paying for an executive while they ramp.

You’re also absorbing the cost of delayed decisions, inconsistent messaging, weak sales enablement and continued CEO involvement in marketing decisions.

That is where the arithmetic changes.

What Waiting Is Actually Costing You

The cost of waiting rarely appears as one obvious line item.

Instead, it shows up across the business.

Sales cycle drag

When there is no clear commercial narrative, sales teams often fill the gap themselves.

One rep leads with the clinical outcome. Another leads with the technology. Someone else focuses on cost savings.

The buyer gets a different version of the story depending on who they speak to.

That creates friction.

Without consistent messaging and clear proof points, objections are harder to handle. Sales enablement becomes reactive. Conversations take longer to move forward.

The result can be a commercial process that feels harder than the product itself.

Market confusion

In MedTech, early positioning matters.

KOLs, clinicians, procurement teams and commercial partners begin forming an opinion about your product through early conversations, presentations and marketing materials.

Those first impressions create a frame.

If the market understands the wrong thing about your product, changing that perception later takes more work.

You may have built something clinically valuable.

But if the market cannot quickly understand why it matters, who it is for and what outcome it creates, the commercial story has a problem.

CEO time leakage

This is often the invisible cost.

When a senior strategy layer doesn’t exist, the CEO becomes the strategy layer.

That doesn’t necessarily mean the CEO is setting the commercial direction.

Instead, they are reviewing copy.

Joining marketing meetings.

Answering positioning questions.

Approving campaigns.

Helping sales respond to objections.

Rewriting investor messaging.

Making decisions that should already have a clear strategic answer.

Every one of those decisions takes time.

And CEO time is usually better spent elsewhere.

On investors. On strategic partnerships. On major customers. On the board. On product direction. On the decisions that only the CEO can make.

The Commercial Window Doesn’t Wait

MedTech companies often reach moments when commercial momentum matters more than usual.

• A regulatory milestone can open a new market conversation.

• A new clinical result can strengthen the evidence story.

• A major customer can create valuable validation.

• A funding round can create pressure to demonstrate commercial progress.

These moments create opportunity.

They also create deadlines.

The market does not pause while you recruit an executive.

Competitors continue positioning themselves. Customers continue forming preferences. Sales teams continue having conversations. Investors continue asking questions.

So the question becomes less about whether you need senior commercial leadership.

It becomes about when you need it to start creating value.

Why Hiring a CMO Can Take Longer Than Expected

There is another part of the equation that often gets overlooked.

The executive search itself takes time.

The right CMO may already be employed. They may not be actively looking. They may need a compelling reason to leave their current role.

That means the company needs a strong story before the search even begins.

Where is the company going?

What is the commercial opportunity?

Why now?

What does success look like?

Why is this role strategically important?

There is an interesting tension here.

You may want a CMO to help define and communicate that story.

But you often need the story to attract the right CMO in the first place.

Then comes the search, interviews, negotiations, notice period and onboarding.

After that comes the ramp.

The result can be a long period between “we need senior commercial leadership” and “we have senior commercial leadership that is fully effective.”

For a company facing a commercial decision today, that timeline may not work.

The Alternative: Put Senior Strategy in Place Before You Hire

This is where the fractional model can make sense.

Not as a cheaper version of a CMO.

As a different operating model.

A genuine fractional commercial leader can bring senior-level strategy into the business without requiring an executive search or a long onboarding period.

The goal is not to add another person producing marketing activity.

It is to create the strategic layer that connects positioning, messaging, sales enablement, go-to-market and commercial priorities.

That distinction matters.

A fractional engagement should not simply give you another consultant with a list of recommendations.

It should help answer the questions your business needs answered now.

• Who are we really selling to?

• What outcome are we selling?

• Why should the market believe us?

• What should sales be saying?

• What should marketing stop doing?

• What needs to happen next?

And perhaps most importantly: Who owns the commercial thinking?

That is the gap many MedTech companies are trying to fill when they start looking for a CMO.

What a Fractional Model Can and Cannot Do

A fractional model is not right for every company.

If you need a full-time executive embedded in the business every day, managing a large marketing function and building an internal team, a permanent hire may be the right structure.

But if the immediate need is senior strategy, commercial clarity and momentum, waiting for a full-time hire may not be necessary.

The right fractional model should give the business access to senior thinking while the company continues to evolve.

It can help establish the commercial architecture.

It can create clarity across marketing and sales.

It can strengthen investor and board storytelling.

It can turn complex MedTech technology into a clearer commercial proposition.

And it can help build the systems and thinking that a future full-time CMO can inherit.

That last point is important.

The goal does not have to be fractional versus full-time.

It can be fractional now, full-time when the business is ready.

Start With Clarity Before Making the Hire

Sometimes the answer is not to immediately commit to either model.

The first step is understanding the commercial problem.

• Where is the friction?

• Is the issue positioning?

• Sales enablement?

• Go-to-market?

• Messaging?

• Market understanding?

• Leadership capacity?

Or is there a deeper problem connecting the product story to the commercial outcome?

A focused strategic intensive can help answer those questions.

The value is not another presentation full of frameworks.

It is clarity.

Clarity about what is holding commercial progress back.

Clarity about what needs to change.

And clarity about the level of leadership the business actually needs next.

That can make the eventual hiring decision much easier.

The Real Question

The question isn’t simply whether you need a CMO.

The better question is: What does the business need from senior commercial leadership right now?

If the CEO is filling a strategy gap they shouldn’t be filling, there is already a cost.

If sales teams are telling different versions of the story, there is already a cost.

If the board is asking commercial questions that don’t have clear answers, there is already a cost.

And if an important commercial window is open, waiting for the perfect executive hire can create another cost: time.

A full-time CMO may ultimately be the right move.

But that doesn’t mean the business needs to wait for one before putting senior commercial strategy in place.

At Tribe, we believe the architecture connecting brand, strategy and revenue should exist before the title does.

Because markets don’t buy outputs. They buy outcomes. And the commercial strategy that connects the two shouldn’t have to wait.

Ready to create more clarity around your commercial strategy?

→ Book a Discovery Call